
GeoVax's Gedeptin® Shows Favorable Safety and Disease Stability in Recurrent Head & Neck Cancer Trial
GeoVax's Phase 1/2 trial of Gedeptin® demonstrated a favorable safety profile and evidence of disease stability in heavily pretreated recurrent head and neck cancer patients, supporting further development in earlier-stage disease and combination therapies.
Read full story

























